Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 56, Issue 5, 2015, Pages 1502-1506

  Yin, Changhong ^a   Sandoval, Claudio ^a   Baeg, Gyeong Hun ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Acute lymphoblastic leukemia; JAK3; Mutant allele

Indexed keywords

INTERLEUKIN 3; JANUS KINASE 3; STAT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL GROWTH; CHILD; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AGE; ALLELE; CELL TRANSFORMATION; CHROMOSOME ABERRATION; GENETICS; METABOLISM; MUTATION; TUMOR CELL LINE;

AGE FACTORS; ALLELES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHROMOSOME ABERRATIONS; HUMANS; JANUS KINASE 3; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84932165506     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.957204     Document Type: Article

References (26)

1. Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for acute lymphoblastic leukemia. Leukemia 2010;24:255-264.
2. Möricke A, Zimmermann M, Reiter A, et al. Longterm results of f ve consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265-284.
3. Pui C, Carroll W, Meshinchi S, et al. Biology, risk stratif cation, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551-565.
4. Locatelli F, Schrappe M, Bernardo M, et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012;120:2807-2816.
5. O'Shea J, Gadina M, Schreiber R. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109(Suppl.): S121-S131.
6. Ghoreschi K, Laurence A, O'Shea J. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-287.
7. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800-802.
8. Park SY, Saijo K, Takahashi T, et al. Developmental defects of lymphoid cells in Jak3 kinase-defcient mice. Immunity 1995;3:771-782.
9. Grossman WJ, Verbsky JW, Yang L, et al. Dysregulated myelopoiesis in mice lacking Jak3. Blood 1999;94:932-939.
10. Rochman Y, Spolski R, Leonard W. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009;9:480-490.
11. Walters D, Mercher T, Gu T, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
12. Choi Y, Kaneda R, Wada T, et al. Identif cation of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res 2007;31:203-209.
13. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007;21:574-576.
14. Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008;112:4220-4226.
15. Sato T, Toki T, Kanezaki R, et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol 2008;141:681-688.
16. Mullighan CG, Zhang J, Harveyc R, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Nati Acad Sci USA 2009;106:9414-9418.
17. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specif c Janus kinase 3 inhibitor. Science 2003;302:875-878.
18. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002;277:47954-47963.
19. Baas AF, Boudeau J, Sapkota GP, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 2003;22:3062-3072.
20. Zhang X, Gureasko J, Shen K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-1149.
21. Argestinger LS, Kouadio JL, Steen H, et al. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 2004;24:4955-4967.
22. Druker BJ, Talpaz M, Resta DJ, et al. Ef cacy and safety of a specif c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
23. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Onc 2009;1:5175-5181.
24. Falchi L, Kantarjian HM, Wang X, et al. Signif cance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013;88:1024-1029.
25. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and ef cacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofbrosis. N Engl J Med 2010;363:1117-1127.
26. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and ef cacy of Tg101348, a selective Jak2 inhibitor, in myelof brosis. J Clin Oncol 2011;29:789-796.